TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29793828
Drug: Full replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full replacement dose testosterone gel with aromatase inhibitor
Study: 24573122
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamins and n‐3 PUFAs
Study: 25211364
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg·kg⁻¹)
Study: 17333971
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg of acetylsalicylic acid (aspirin) ingested 24 hours before blood donation
Study: 11575417
Drug: remifentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 0.5 microg kg(‐1) followed by an infusion of 0.1 microg kg min(‐1)
Study: 11575417
Drug: alfentanil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 10 microg kg(‐1) followed by an infusion of saline
Study: 7181051
Drug: High single
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High single dose (greater than or equal to 1,000 biological units)
Study: 7181051
Drug: High nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High nasal sensitivity before treatment
Study: 7181051
Drug: Repetition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetition of a single dose
Study: 7181051
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses (greater than or equal to 5,000 biological units)
Study: 7181051
Drug: Initial preseasonal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial preseasonal therapy
Study: 7181051
Drug: Subsequent perennial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent perennial dosage
Study: 10396521
Drug: Interview administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interview administration of questionnaire
Study: 10396521
Drug: Postal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postal administration of questionnaire
Study: 8041988
Drug: Weekly chemotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly chemotherapy with 7 active drugs (cyclophosphamide + adriamycin + etoposide on day 1; cisplatin + vindesine on day 8; methotrexate + vincristine on day 15)
Study: 17535634
Drug: SGD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGD group (100 mg Tobramycin, 40 mg garlicin, and 20% Lactulose for 10 ml three times per day for 3 days)
Study: 17535634
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (preoperative bowel preparation: diet preparation and enema)
Study: 15194029
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hyperbaric oxygen therapy)
Study: 8056008
Drug: Elgodipine 20
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elgodipine 20 mg
Study: 8056008
Drug: Elgodipine 40
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elgodipine 40 mg
Study: 8056008
Drug: Elgodipine 60
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elgodipine 60 mg
Study: 31397129
Drug: Grain-moxibustion combined
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grain-moxibustion combined with medicine therapy (vitamin E capsules and Wuzi Yanzong pills)
Study: 31397129
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vitamin E capsules and Wuzi Yanzong pills)
Study: 31397129
Drug: Grain-moxibustion combined
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grain-moxibustion combined with medicine therapy
Study: 25088520
Drug: structured dietary
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: structured dietary treatment
Study: 25088520
Drug: physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: physical exercise treatment
Study: 23562754
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid therapy (40 mg omeprazole and 1 g amoxicillin, twice daily for 14 days; 500 mg clarithromycin and 500 mg nitroimidazole added, twice daily for the final 7 days)
Study: 23562754
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (same 4 drugs taken concurrently, twice daily for 14 days)
Study: 3935377
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fluvoxamine as a single daytime dose
Study: 3935377
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fluvoxamine as a single night-time dose
Study: 3935377
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg fluvoxamine twice daily
Study: 29720146
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS reminders in addition to usual treatment
Study: 27558186
Drug: Androstenedione (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androstenedione (300 mg for 7 days)
Study: 2125681
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (SK) with heparin
Study: 2125681
Drug: Alteplase (t-PA)
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase (t-PA) with or without heparin
Study: 30778546
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acupuncture and herbal medicine
Study: 23467207
Drug: L-citrulline (100mg/kg)
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-citrulline (100mg/kg)
Study: 21502796
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg tid) with normo-caloric diet
Study: 17870038
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg elemental calcium daily for 12 months)
Study: 31660823
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (DAAO inhibitor), 2 g per day for 6 weeks
Study: 25232809
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 μg per day from L-selenomethionine)
Study: 16369811
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + MPA (0.625 mg/day + 2.5 mg/day)
Study: 12771456
Drug: Intracystic injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAGASTRIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracystic injection of recombinant interleukin-2 (rIL-2)
Study: 9078538
Drug: Postoperative thyroid
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative thyroid hormone levels after cardiac surgery
Study: 9078538
Drug: Postoperative urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative urinary iodine excretion
Study: 9078538
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with postoperative T3 plasma concentrations less than 0.6 nmol/L
Study: 9078538
Drug: Cumulative doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative doses of inotropic and vasoactive catecholamines and furosemide
Study: 29798075
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin as bridge therapy
Study: 25656505
Drug: Cognitive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive intervention program (multidomain cognitive stimulation including art, music, recollection, and horticultural therapy, 1 hour each session, 5 times per week for 6 months)
Study: 25656505
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pharmacotherapy only)
Study: 25010104
Drug: Therapy sessions
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy sessions (6 weekly 1-hour sessions)
Study: 22159005
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (4 times a day with subsequent reduction)
Study: 17881145
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + short-course hormone therapy (STH)
Study: 17881145
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + long-term hormone therapy (LTH)
Study: 18259090
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg propranolol (Inderal)
Study: 29368599
Drug: Nasal Highflow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Highflow (NHF) at 20 L/min, low leakage
Study: 29368599
Drug: Nasal Highflow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Highflow (NHF) at 40 L/min, low leakage
Study: 29368599
Drug: Nasal Highflow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Highflow (NHF) at 40 L/min, high leakage (one prong outside and open)
Study: 29368599
Drug: Nasal Highflow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Highflow (NHF) at 40 L/min, high leakage (one prong outside and closed)
Study: 29368599
Drug: Nasal Highflow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Highflow (NHF) at 40 L/min, low leakage (condition B)
Study: 27450228
Drug: Alectinib (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib (exact dosage and duration not specified)
Study: 27450228
Drug: Esomeprazole (gastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (gastric acid-reducing agent, exact dosage and duration not specified)
Study: 15674313
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g CLA isomer blend (50:50% cis-9,trans-11:trans-10,cis-12 isomers)
Study: 12666951
Drug: EDTA gel
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA gel conditioning for 2 minutes (G3)
Study: 12666951
Drug: EDTA gel
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA gel conditioning for 2 minutes after scaling and root planing (G4)
Study: 12666951
Drug: EDTA gel
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA gel conditioning for 4 minutes after scaling and root planing (G5)
Study: 12666951
Drug: EDTA gel
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA gel conditioning for 4 minutes (G5)
Study: 7105952
Drug: Loperamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (4 mg tds)
Study: 19254366
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of IGOB131
Study: 8874746
Drug: Topical melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical melatonin 0.5%
Study: 8874746
Drug: Topical melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical melatonin 0.05%
Study: 30761783
Drug: Fosfomycin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin + Phytolysin (3g fosfomycin single dose, Phytolysin three times daily for a month)
Study: 30761783
Drug: Fosfomycin (3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (3g single dose)
Study: 22955035
Drug: UMEC/VI (500/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC/VI (500/25 mcg)
Study: 18622640
Drug: Pyridostigmine (180-540
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (180-540 mg daily for 6 weeks)
Study: 10598611
Drug: Epidural lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural lidocaine (300 mg)
Study: 10598611
Drug: Epidural saline-intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline-intravenous lidocaine infusion
Study: 8524760
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy and a course of microwave therapy
Study: 1957647
Drug: Myoblast injection
Normalized name: Bioblast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoblast injection (approximately 8 x 10(6) myoblasts)
Study: 1957647
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (carrier solution)
Study: 1957647
Drug: Myoblast injection
Normalized name: Bioblast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoblast injection with Cyclosporine (CsA) treatment (started two days before injection and continued for three months)
Study: 23381945
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in patients with moderate Wwox expression
Study: 23381945
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in patients with strong Wwox expression
Study: 21181319
Drug: Esomeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (80 mg/30 minutes, then 8 mg/hour for 71.5 hours)
Study: 15585551
Drug: Original dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original dose of T4 (control group)
Study: 12038448
Drug: Three-step high-dose
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-step high-dose chemotherapy (HDT) with autologous peripheral blood progenitor cell (PBPC) transplant
Study: 12038448
Drug: Three-step high-dose
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-step high-dose chemotherapy (HDT)
Study: 26172895
Drug: Patiromer 4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 4.2 g twice daily
Study: 26172895
Drug: Patiromer 8.4
Normalized name: patiromer 8.4 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 8.4 g twice daily
Study: 26172895
Drug: Patiromer 12.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 12.6 g twice daily
Study: 26172895
Drug: Patiromer 8.4
Normalized name: patiromer 8.4 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 8.4 g twice daily (moderate hyperkalemia)
Study: 26172895
Drug: Patiromer 12.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 12.6 g twice daily (moderate hyperkalemia)
Study: 26172895
Drug: Patiromer 16.8
Normalized name: patiromer 16.8 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 16.8 g twice daily (moderate hyperkalemia)
Study: 26172895
Drug: Patiromer (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer (all doses)
Study: 16441622
Drug: BMV 0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMV 0.12% cream
Study: 15313287
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 0.4% ophthalmic solution (Acular(R) LS), n = 156, 4 times daily for up to 4 days
Study: 15313287
Drug: Vehicle (control),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (control), n = 157, 4 times daily for up to 4 days
Study: 27406346
Drug: Neratinib added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib added to standard neoadjuvant chemotherapy
Study: 27406346
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy with trastuzumab (Control)
Study: 28130435
Drug: GnRH-antagonist protocol
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH-antagonist protocol
Study: 24927078
Drug: long‐GnRH‐agonist protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: long‐GnRH‐agonist protocol
Study: 21880023
Drug: 12 week
Normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 week exercise program including aerobic and strengthening exercises, conducted between week 20 and 36 of pregnancy, with one weekly group session led by physiotherapists and home exercises encouraged twice a week.
Study: 20557387
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (laxatives)
Study: 18407413
Drug: Leech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leech therapy (2-3 locally applied leeches)
Study: 18407413
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (30-day course, twice a day)
Study: 11874430
Drug: Glibenclamide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (15 mg/day)
Study: 11874430
Drug: Glimepiride (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (6 mg/day)
Study: 10195783
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine with immune globulin (Ig) concurrently
Study: 7851164
Drug: Medical and
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical and surgical treatment
Study: 7851164
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (anal surgeries including abscess drainage and fistulotomy)
Study: 387010
Drug: Flunisolide intranasal
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide intranasal spray
Study: 31687867
Drug: Virtual reality-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-delivered mirror visual feedback (VR-MVF) and exposure therapy (VR-ET)
Study: 26848148
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg LD/10 mg MD q.d.)
Study: 26848148
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg LD/90 mg MD b.i.d)
Study: 26848148
Drug: Clopidogrel (previous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (previous treatment)
Study: 25452426
Drug: Umeclidinium/vilanterol (UMEC/VI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium/vilanterol (UMEC/VI) 125/25 mcg
Study: 22238169
Drug: No PEP
Normalized name: Jalapeno pepper
DrugBank: Capsicum (DB10897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No PEP (daily symptom monitoring)
Study: 20028938
Drug: 20% intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% intralipid infusion at 40 ml/h for 48 h
Study: 16010209
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy followed by autologous stem cell transplantation (HDT-ASCT)
Study: 10663427
Drug: 0.50 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 g/kg of 10% (v/v) alcohol solution
Study: 10663427
Drug: 0.75 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g/kg of 10% (v/v) alcohol solution
Study: 10663427
Drug: 0.00 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.00 g/kg of 10% (v/v) alcohol solution
Study: 10663427
Drug: 0.25 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g/kg of 10% (v/v) alcohol solution
Study: 1298086
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg total dose of artemether given over 5 days
Study: 1298086
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg total dose of artemether given over 5 days
Study: 1298086
Drug: Both dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosage regimens (480 mg and 600 mg)
Study: 6094446
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous injection of cefotaxime at the time of induction of anaesthesia
Study: 30043658
Drug: ozanimod hydrochloride
Normalized name: Ozanimod Hydrochloride
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ozanimod hydrochloride 0.5 mg
Study: 30043658
Drug: ozanimod hydrochloride
Normalized name: Ozanimod Hydrochloride
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ozanimod hydrochloride 1 mg
Study: 30043658
Drug: placebo →
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo → ozanimod hydrochloride 0.5 mg
Study: 30043658
Drug: placebo →
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo → ozanimod hydrochloride 1 mg
Study: 12093068
Drug: Medical Treatment
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Treatment (MT) for stroke prevention including antiplatelet agents, lipid-lowering drugs, diabetic and hypertension control.
Study: 10530683
Drug: Topical agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agents
Study: 11836038
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined therapy
Study: 6372981
Drug: 6-thioguanine (6-TG)
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-thioguanine (6-TG) in nonrandomized arm for previously drug-resistant tumors
Study: 31673419
Drug: tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 5 mg two times per day monotherapy
Study: 31673419
Drug: tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 5 mg two times per day + MTX
Study: 31673419
Drug: adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: adalimumab (ADA) 40 mg every other week + MTX
Study: 29807091
Drug: Virtual triage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual triage algorithm with MR‐proADM cut-off of 0.80 nmol/L
Study: 26967331
Drug: 6 doses
Normalized name: interferon alfa-2b,recomb. 3 million unit/0.2 mL (6 doses per pen = 18 million unit) SUBCUT PEN INJECTOR KIT (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 doses albendazole
Study: 26967331
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses albendazole
Study: 9251955
Drug: Subtotal perineoplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtotal perineoplasty and interferon (IFN) injections
Study: 8126628
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with surfactant (Curosurf) at a dosage of 200 mg/kg